Johnson & JohnsonvsProtalix BioTherapeutics

JNJ and PLX stock compared: price, dividend, valuation and results, from SEC filings.

PLX

Protalix BioTherapeutics, Inc.

$3.02

Value $243M

+4.86%
PLX's page

Johnson & Johnson (JNJ) has a market value of $657B and Protalix BioTherapeutics (PLX) $243M. Over the last year, with dividends, JNJ moved +39.7% and PLX +59.8%. The P/E is 40.8 for JNJ and 11.8 for PLX. Dividend yield: JNJ 1.94%, PLX none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    JNJ$657B

    PLX$243M

    JNJ is 2,701 times PLX

  • Revenue, 12 months

    JNJ$99.3B

    PLX$85M

    JNJ is 1,173 times PLX

  • Net income, 12 months

    JNJ$16.1B

    PLX$21M

    JNJ is 783 times PLX

  • Operating margin

    JNJ–

    PLX29.8%

  • ROIC

    JNJ12.4%

    PLX31.3%

    18.9 points apart

  • P/E

    JNJ40.8

    PLX11.8

    JNJ is 3.4 times PLX

  • Dividend yield

    JNJ1.9%

    PLX0.0%

    1.9 points apart

  • 5-year return

    JNJ+92.0%

    PLX+184.9%

    92.9 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

JNJ+92.0%

PLX+184.9%

10020030020222023202420252026
Returns by period
PeriodJNJWith dividendsPLXWith dividends
1 year since November 17, 2025+39.7%Price +36.6%+59.8%Price +59.8%
3 years since November 17, 2023+98.2%+25.6% a yearPrice +82.1%+115.7%+29.2% a yearPrice +115.7%
5 years since November 17, 2021+92.0%+13.9% a yearPrice +67.0%+184.9%+23.3% a yearPrice +184.9%
10 years since November 18, 2016+208.0%+11.9% a yearPrice +136.4%-38.4%-4.7% a yearPrice -38.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

JNJJohnson & JohnsonPLXProtalix BioTherapeutics

Valuation

JNJPLX
Valuation
Price$272.70$3.02
Market value$657B$243M
Enterprise value (EV)$685B$221M
P/E40.811.8
P/E, 5-year median21.9–
P/B8.13.0
EV/EBIT38.68.8
Free cash flow yield3.1%6.2%

Results and growth

JNJPLX
Results and growth
Revenue, 12 months$99.3B$85M
Net income, 12 months$16.1B$21M
Free cash flow, 12 months$20.6B$15M
Earnings per share, 12 months$6.59$0.25
Revenue growth, year on year6.1%-1.2%
Revenue growth a year, past+2.7%over 5 years-3.5%over 5 years
EPS growth a year, past+14.9%over 5 years–

Margins and returns on capital

JNJPLX
Margins and returns on capital
Gross margin67.6%71.2%
Operating margin–29.8%
Net margin16.2%24.3%
ROIC12.4%31.3%
ROE19.7%32.1%

Balance sheet

JNJPLX
Balance sheet
Cash$17.2B$22M
Total debt$44.7B$9.1M
Net debt / EBITDA1.1-0.8
Interest cover18.0×–

Dividends and buybacks

JNJPLX
Dividends and buybacks
Dividend yield1.9%–
Dividend per share, 12 months$5.28–
Dividend growth a year, past+5.3%over 5 years–
Buyback yield0.9%–
Shareholder yield2.9%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: JNJ or PLX

Didn't find what you were looking for?

Ask us
Which is bigger, Johnson & Johnson or Protalix BioTherapeutics?

By market value, Johnson & Johnson ($657B) is about 2,700.8 times Protalix BioTherapeutics ($243M), at today's prices.

How did JNJ and PLX stock do over the last 10 years?

Since November 18, 2016, JNJ's price moved +136.4% and PLX's -38.4%. With dividends: JNJ +208.0% (+11.9% a year), PLX -38.4% (-4.7% a year). Past returns do not predict future ones.

Which pays the higher dividend, JNJ or PLX?

The dividend yield at today's price is 1.94% for Johnson & Johnson and none for Protalix BioTherapeutics. Over the last twelve months they paid $5.28 and – per share.

What is the P/E of JNJ and PLX?

At today's price, the P/E is 40.8 for JNJ and 11.8 for PLX. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Johnson & Johnson or Protalix BioTherapeutics?

Over the last twelve months, the net margin was 16.2% for Johnson & Johnson and 24.3% for Protalix BioTherapeutics, and the operating margin – and 29.8%. Revenue was $99.3B and $85M.

Which is the better investment, Johnson & Johnson or Protalix BioTherapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.